Advancing Molecular Glue Discovery through a Positive-Signal Bacterial Screening Platform

• Combining in-silico with the power of our bacteria-based, synthetic positive selection screening system for new molecular glues
• Program insights covering oncology and non-oncology programs, with focus on ligase diversity, target specificity, and optimization process
• Future directions that include expanding beyond degraders to explore non-degraders and PPI modulators, supporting both scientific advancement and company growth strategy 

Speakers:

Orli Even-Or

Director of R&D

Coltac Therapeutics